Artesunate Vaginal Inserts for the Treatment of Cervical Intraepithelial Neoplasia (CIN2/3)

Recruiting

Phase 2

Artesunate Vaginal InsertsArtesunate Vaginal Inserts for the Treatment of Cervical Intraepithelial Neoplasia (CIN2/3)

Sponsor:

Frantz Viral Therapeutics, LLC

Code:

NCT04098744

Conditions

CIN 2/3

HPV Infection

Pre-Cancerous Dysplasia

Cervical Dysplasia

HPV Related Disease

Eligibility Criteria

Sex: Female

Age: 25 - 70+

Healthy Volunteers: Not accepted

Interventions

Artesunate vaginal insert

Placebo vaginal insert

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-12-04. This information was provided to ClinicalTrials.gov by Frantz Viral Therapeutics, LLC on 2025-10-02.